ASH 2022 | The prognostic impact of FLT3-ITD and FLT3-TKD in NPM1-mutated AML
Onyee Chan, MD, Moffitt Cancer Center, Tampa, FL, discusses the findings from a study that examined the impact of FLT3 and NPM1 co-mutation in patients with acute myeloid leukemia (AML), and further investigated whether the type of FLT3 mutation (FLT3-ITD or FLT3-TKD) impacted prognosis and survival outcomes. The study found that patients harboring an NPM1 mutation and both FLT3-ITD and FLT3-TKD had a very poor prognosis and a shorter overall survival (OS) than those who harbored only one of the FLT3 mutations. Dr Chan also highlights the importance of conducting more research to better understand how these mutations interact with NPM1. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Syntrix Pharmaceuticals: Research Funding.
